State of Alaska Department of Revenue Sells 79,691 Shares of Certara, Inc. (NASDAQ:CERT)

State of Alaska Department of Revenue cut its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 40.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 117,549 shares of the company's stock after selling 79,691 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.07% of Certara worth $1,163,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of CERT. Rhumbline Advisers lifted its holdings in Certara by 4.0% during the 4th quarter. Rhumbline Advisers now owns 277,452 shares of the company's stock worth $2,955,000 after purchasing an additional 10,739 shares during the last quarter. Principal Financial Group Inc. increased its position in Certara by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock worth $5,660,000 after buying an additional 15,739 shares during the period. CIBC Asset Management Inc bought a new position in Certara during the 4th quarter worth $132,000. Venturi Wealth Management LLC lifted its holdings in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares in the last quarter. Finally, Private Advisor Group LLC bought a new stake in shares of Certara in the fourth quarter valued at about $251,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Wall Street Analyst Weigh In

CERT has been the subject of several analyst reports. KeyCorp lifted their price objective on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective for the company. William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, Robert W. Baird raised their target price on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $15.67.

Certara Trading Down 0.4%

CERT stock traded down $0.04 during mid-day trading on Friday, reaching $11.38. The company's stock had a trading volume of 2,205,514 shares, compared to its average volume of 1,434,337. The company has a market cap of $1.85 billion, a price-to-earnings ratio of 34.61 and a beta of 1.44. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $16.93. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. The business's 50 day moving average price is $11.99 and its 200 day moving average price is $11.85.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The company had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter in the previous year, the company earned $0.10 EPS. Certara's quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.